Downloads provided by UsageCountsPlease grant OpenAIRE to access and update your ORCID works.
This Research product is the result of merged Research products in OpenAIRE.
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
This Research product is the result of merged Research products in OpenAIRE.
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Antibody Characterization Report for Profilin-1
McDowell, Ian; Ayoubi, Riham; Ryan, Joel; Fotouhi, Maryam; Reintsch, Wolfgang; Durcan, Thomas M.; Brown, Claire M.; +2 Authors
McDowell, Ian; Ayoubi, Riham; Ryan, Joel; Fotouhi, Maryam; Reintsch, Wolfgang; Durcan, Thomas M.; Brown, Claire M.; McPherson, Peter S.; Laflamme, Carl;
Antibody Characterization Report for Profilin-1
Head-to-head comparison of available commercial antibodies against Profilin-1 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. Work reported in this report was supported in part by the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities: the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
amyotrophic lateral sclerosis, antibody characterization, P07737, PFN1, Profilin-1, antibody validation, ALS-RAP
amyotrophic lateral sclerosis, antibody characterization, P07737, PFN1, Profilin-1, antibody validation, ALS-RAP
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average views 97 downloads 87 citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average - 97views87downloads
popularity
Popularity provided by BIP!
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
Popularity provided by BIP!influenceInfluence provided by BIP!
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Influence provided by BIP!impulseImpulse provided by BIP!
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
Impulse provided by BIP!viewsViews provided by UsageCounts
Views provided by UsageCountsdownloadsDownloads provided by UsageCounts
Downloads provided by UsageCounts Average
Average
Average
97
87
Head-to-head comparison of available commercial antibodies against Profilin-1 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. Work reported in this report was supported in part by the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities: the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.